Philip Seeman: Difference between revisions
Content deleted Content added
Changed to past tense |
GreenRunner0 (talk | contribs) mNo edit summary |
||
| Line 7: | Line 7: | ||
|caption = |
|caption = |
||
|birth_date = {{BirthDeathAge|df=yes|B|1934|2|8|2021|1|9|yes}} |
|birth_date = {{BirthDeathAge|df=yes|B|1934|2|8|2021|1|9|yes}} |
||
|birth_place = Winnipeg, Manitoba |
|birth_place = [[Winnipeg]], [[Manitoba]], Canada |
||
|death_date = {{BirthDeathAge|df=yes||1934|2|8|2021|1|9|yes}} |
|death_date = {{BirthDeathAge|df=yes||1934|2|8|2021|1|9|yes}} |
||
|death_place = |
|death_place = [[Toronto]], [[Ontario]], Canada |
||
|other_names = |
|other_names = |
||
|known_for = |
|known_for = |
||
| Line 16: | Line 16: | ||
|awards = [[Order of Canada]] |
|awards = [[Order of Canada]] |
||
}} |
}} |
||
'''Philip Seeman''', {{Post-nominals|country=CAN|OC|FRSC}} (February 8, 1934 |
'''Philip Seeman''', {{Post-nominals|country=CAN|OC|FRSC}} (February 8, 1934 – January 9, 2021) was a Canadian [[schizophrenia]] researcher and [[neuropharmacology|neuropharmacologist]], known for his research on [[dopamine]] receptors.<ref>{{cite web |title=Philip SEEMAN |url=https://www.legacy.com/obituaries/theglobeandmail/obituary.aspx?n=philip-seeman&pid=197516322 |publisher=The Globe and Mail |access-date=19 January 2021}}</ref> |
||
Born in [[Winnipeg]], [[Manitoba]], Seeman was raised in [[Montreal]]. He received a [[Bachelor of Science]] degree, honours physics & physiology (1955), a [[Master of Science]] degree, physiology of transport & secretion (1956), and a [[Doctor of Medicine]] (1960) from [[McGill University]]. In 1966, he received a Ph.D. in life sciences from [[Rockefeller University]]. |
Born in [[Winnipeg]], [[Manitoba]], Seeman was raised in [[Montreal]]. He received a [[Bachelor of Science]] degree, honours physics & physiology (1955), a [[Master of Science]] degree, physiology of transport & secretion (1956), and a [[Doctor of Medicine]] (1960) from [[McGill University]]. In 1966, he received a Ph.D. in life sciences from [[Rockefeller University]]. |
||
Revision as of 06:06, 25 January 2021
 | This article is an autobiography or has been extensively edited by the subject or by someone connected to the subject. (February 2013) |
Philip Seeman | |
|---|---|
| Born | 8 February 1934 |
| Died | 9 January 2021 (aged 86) |
| Awards | Order of Canada |
Philip Seeman, OC FRSC (February 8, 1934 – January 9, 2021) was a Canadian schizophrenia researcher and neuropharmacologist, known for his research on dopamine receptors.[1]
Born in Winnipeg, Manitoba, Seeman was raised in Montreal. He received a Bachelor of Science degree, honours physics & physiology (1955), a Master of Science degree, physiology of transport & secretion (1956), and a Doctor of Medicine (1960) from McGill University. In 1966, he received a Ph.D. in life sciences from Rockefeller University.
In 1967, Seeman became an assistant professor in the Department of Pharmacology at the University of Toronto. In 1970, he was appointed a professor.
In 1974, having spent years in search of the binding site of antipsychotic medication, he discovered the dopamine D2 receptor, the basis for the dopamine hypothesis of schizophrenia.[2][3]
In 2001, he was made an Officer of the Order of Canada "for his research on dopamine receptors and their involvement in diseases such as schizophrenia, Parkinson's and Huntington's".[4]
In 1985, he was made a Fellow of the Royal Society of Canada.[5]
He was married to Dr. Mary V. Seeman.[6]
Notes
- ^ "Philip SEEMAN". The Globe and Mail. Retrieved 19 January 2021.
- ^ P. Seeman, M. Chau-Wong, J. Tedesco & K. Wong (November 1975). "Brain receptors for antipsychotic drugs and dopamine: direct binding assays". Proceedings of the National Academy of Sciences of the United States of America. 72 (11): 4376–4370. Bibcode:1975PNAS...72.4376S. doi:10.1073/pnas.72.11.4376. PMC 388724. PMID 1060115.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ "People". CMAJ. 151 (8): 1186–1187. 1994. PMC 1337253.
- ^ Order of Canada citation
- ^ http://www.sciandmed.com/sm/journalviewer.aspx?issue=1066&article=787&action=1
- ^ "Most Wikipedia profiles are about men – these women in Australia are hoping to change that". SBS News. Retrieved 27 July 2019.
References
- Madras, B.K. (2013). "History of the discovery of the antipsychotic dopamine D2 receptor: A basis for the dopamine hypothesis of schizophrenia". Journal of the History of the Neurosciences: Basic and Clinical Perspectives. 22 (1): 62–78. doi:10.1080/0964704x.2012.678199. PMID 23323533.
- Seeman, P. (2011). "All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2High receptors". CNS Neuroscience and Therapeutics. 17 (2): 118–132. doi:10.1111/j.1755-5949.2010.00162.x. PMC 6493870. PMID 20560996.
- P. Seeman (2010). "Dopamine D2 Receptors as Treatment Targets in Schizophrenia. Clinical Schizophrenia & Related Psychoses April: 56-73.
- P. Seeman (2007), Scholarpedia, 2(10): 3634 doi.4249/scholarpedia.3634
- Seeman, P. (2006). "Targeting the dopamine D2 receptor in schizophrenia". Expert Opinion on Therapeutic Targets. 10 (4): 515–531. doi:10.1517/14728222.10.4.515. PMID 16848689.
- Seeman, P.; Weinshenker, D.; Quirion, R.; Srivastava, L.; Bhardwaj, S.K.; Grandy, D.K.; Premont, R.; Sotnikova, T.; Boksa, P.; El-Ghundi, M.; O'Dowd, B.F.; George, S.R.; Perreault, M.L.; Mannisto, P.T.; Robinson, S.; Palmiter, R.D.; Tallerico, T. (2005). "Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis". Proceedings of the National Academy of Sciences USA. 102 (9): 3513–3518. Bibcode:2005PNAS..102.3513S. doi:10.1073/pnas.0409766102. PMC 548961. PMID 15716360.
- Seeman, P.; Chau-Wong, M.; Tedesco, J.; Wong, K. (1975). "Brain receptors for antipsychotic drugs and dopamine: Direct binding assays". Proceedings of the National Academy of Sciences, USA. 72 (11): 4376–4380. Bibcode:1975PNAS...72.4376S. doi:10.1073/pnas.72.11.4376. PMC 388724. PMID 1060115.
External links
- Home Page of Philip Seeman's Laboratory
- Probing the Biology of Psychosis, Schizophrenia, and Antipsychotics: An Expert Interview With Dr. Philip Seeman, MD, PhD – an interview on the Medscape website
- Schizophrenia – an essay by Philip Seeman, November 2001
| International | |
|---|---|
| National | |
